Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trazpiroben
- Development stage
- Phase 2
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trazpiroben (TAK-906) is a peripherally selective dopamine D2 and D3 receptor antagonist developed for the treatment of gastroparesis. It was designed to minimize central nervous system and cardiovascular side effects commonly associated with other dopamine antagonists by exhibiting minimal brain penetration and low affinity for the hERG potassium channel. Trazpiroben increases prolactin levels in humans as a marker of peripheral D2 receptor antagonism. The drug was originally developed by Altos Therapeutics and later by Takeda Oncology but its clinical development was discontinued before April 2022[1][4][5][6].
- Other names
- trazpirobenTAK-906TAK906TAK 906ATC-1906ATC1906ATC 1906
02
Targets
DRD4 (Dopamine D4 Receptor)ADRA1B (α1B)DRD1 (Dopamine D1 Receptor)KCNH2 (Voltage-gated potassium channel subfamily H member 2)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on trazpiroben.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trazpiroben.